{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:23:58Z","timestamp":1778729038949,"version":"3.51.4"},"reference-count":33,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: To investigate the correlation of HRCT findings with pulmonary metabolic activity in the corresponding regions using 18F-FDG PET\/CT and inflammatory markers in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD). Methods: This was a cross-sectional study involving 23 adult patients with SSc-associated ILD without other connective tissue diseases. The study also involved 18F-FDG PET\/CT, HRCT, determination of serum chemokine levels, clinical data, and pulmonary function testing. Results: In this cohort of patients with long-term disease (disease duration, 11.8 \u00b1 8.7 years), a nonspecific interstitial pneumonia pattern was found in 19 (82.6%). Honeycombing areas had higher median standardized uptake values (1.95; p = 0.85). Serum levels of soluble tumor necrosis factor receptor 1, soluble tumor necrosis factor receptor 2, C-C motif chemokine ligand 2 (CCL2), and C-X-C motif chemokine ligand 10 were higher in SSc patients than in controls. Serum levels of CCL2-a marker of fibroblast activity-were correlated with pure ground-glass opacity (GGO) areas on HRCT scans (p = 0.007). 18F-FDG PET\/CT showed significant metabolic activity for all HRCT patterns. The correlation between serum CCL2 levels and GGO on HRCT scans suggests a central role of fibroblasts in these areas, adding new information towards the understanding of the mechanisms surrounding cellular and molecular elements and their expression on HRCT scans in patients with SSc-associated ILD. Conclusions: 18F-FDG PET\/CT appears to be unable to differentiate the intensity of metabolic activity across HRCT patterns in chronic SSc patients. The association between CCL2 and GGO might be related to fibroblast activity in these areas; however, upregulated CCL2 expression in the lung tissue of SSc patients should be investigated in order to gain a better understanding of this association.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20210329","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T18:57:28Z","timestamp":1663873048000},"page":"e20210329","source":"Crossref","is-referenced-by-count":8,"title":["PET\/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3072-2763","authenticated-orcid":false,"given":"Andr\u00e9a","family":"L Bastos1","sequence":"first","affiliation":[{"name":"1. Departamento de Anatomia e Imagem, Faculdade de Medicina, Universidade Federal de Minas Gerais \u2013 UFMG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-7261","authenticated-orcid":false,"given":"Gilda","family":"A Ferreira2","sequence":"additional","affiliation":[{"name":"2. Departamento do Aparelho Locomotor, Faculdade de Medicina, Universidade Federal de Minas Gerais \u2013 UFMG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-0954","authenticated-orcid":false,"given":"Marcelo","family":"Mamede1","sequence":"additional","affiliation":[{"name":"1. Departamento de Anatomia e Imagem, Faculdade de Medicina, Universidade Federal de Minas Gerais \u2013 UFMG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-875X","authenticated-orcid":false,"given":"Eliane","family":"V Mancuzo3","sequence":"additional","affiliation":[{"name":"3. Departamento de Cl\u00ednica M\u00e9dica, Faculdade de Medicina, Universidade Federal de Minas Gerais \u2013 UFMG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-3008","authenticated-orcid":false,"given":"Mauro","family":"M Teixeira4","sequence":"additional","affiliation":[{"name":"4. Departamento de Bioqu\u00edmica e Imunologia, Instituto de Ci\u00eancias Biol\u00f3gicas, Faculdade de Medicina, Universidade Federal de Minas Gerais \u2013 UFMG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-3708","authenticated-orcid":false,"given":"Fl\u00e1via","family":"P S T Santos5","sequence":"additional","affiliation":[{"name":"5. Servi\u00e7o de Reumatologia, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade Federal de Minas Gerais \u2013 UFMG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-7804","authenticated-orcid":false,"given":"Cid","family":"S Ferreira6","sequence":"additional","affiliation":[{"name":"6. Departamento de Radiologia, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade Federal de Minas Gerais \u2013 UFMG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1779-0443","authenticated-orcid":false,"given":"Ricardo","family":"A Correa3","sequence":"additional","affiliation":[{"name":"3. Departamento de Cl\u00ednica M\u00e9dica, Faculdade de Medicina, Universidade Federal de Minas Gerais \u2013 UFMG \u2013 Belo Horizonte (MG) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.            Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-320. https:\/\/doi.org\/10.1016\/S2213-2600(19)30480-1","DOI":"10.1016\/s2213-2600(19)30480-1"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.            Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford). 2009;48 Suppl 3:iii40-iii44. https:\/\/doi.org\/10.1093\/rheumatology\/kep109","DOI":"10.1093\/rheumatology\/kep109"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.            Taylor JG, Bolster MB. Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. J Clin Rheumatol. 2003;9(4):239-245. https:\/\/doi.org\/10.1097\/01.rhu.0000083860.27509.f1","DOI":"10.1097\/01.rhu.0000083860.27509.f1"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.            de Souza RB, Borges CT, Capelozzi VL, Parra ER, Jatene FB, Kavakama J, et al. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration. 2009;77(4):389-397. https:\/\/doi.org\/10.1159\/000156958","DOI":"10.1159\/000156958"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.            Mathieson JR, Mayo JR, Staples CA, M\u00fcller NL. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology. 1989 Apr;171(1):111-6. https:\/\/doi.org\/10.1148\/radiology.171.1.2928513","DOI":"10.1148\/radiology.171.1.2928513"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.            Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47(9):738-742. https:\/\/doi.org\/10.1136\/thx.47.9.738","DOI":"10.1136\/thx.47.9.738"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.            Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford). 2008;47 Suppl 5:v59-v61. https:\/\/doi.org\/10.1093\/rheumatology\/ken271","DOI":"10.1093\/rheumatology\/ken271"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.            Nishiyama Y, Yamamoto Y, Dobashi H, Kameda T. Clinical value of 18F-fluorodeoxyglucose positron emission tomography in patients with connective tissue disease. Jpn J Radiol. 2010;28(6):405-413. https:\/\/doi.org\/10.1007\/s11604-010-0445-x","DOI":"10.1007\/s11604-010-0445-x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.            Capitanio S, Nordin AJ, Noraini AR, Rossetti C. PET\/CT in nononcological lung diseases: current applications and future perspectives. Eur Respir Rev. 2016;25(141):247-258. https:\/\/doi.org\/10.1183\/16000617.0051-2016","DOI":"10.1183\/16000617.0051-2016"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.          Chen DL, Bedient TJ, Kozlowski J, Rosenbluth DB, Isakow W, Ferkol TW, et al. [18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation. Am J Respir Crit Care Med. 2009;180(6):533-539. https:\/\/doi.org\/10.1164\/rccm.200904-0501OC","DOI":"10.1164\/rccm.200904-0501oc"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.          Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET\/CT. J Nucl Med. 2009;50(4):538-545. https:\/\/doi.org\/10.2967\/jnumed.108.057901","DOI":"10.2967\/jnumed.108.057901"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.          Chen DL, Rosenbluth DB, Mintun MA, Schuster DP. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol (1985). 2006;100(5):1602-1609. https:\/\/doi.org\/10.1152\/japplphysiol.01429.2005","DOI":"10.1152\/japplphysiol.01429.2005"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.          Win T, Lambrou T, Hutton BF, Kayani I, Screaton NJ, Porter JC, et al. 18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging. 2012;39(3):521-528. https:\/\/doi.org\/10.1007\/s00259-011-1986-7","DOI":"10.1007\/s00259-011-1986-7"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.          Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol. 2012;2012:121439. https:\/\/doi.org\/10.1155\/2012\/121439","DOI":"10.1155\/2012\/121439"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.          Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med. 2014;35(2):181-200. https:\/\/doi.org\/10.1055\/s-0034-1371527","DOI":"10.1055\/s-0034-1371527"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.          van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747. https:\/\/doi.org\/10.1002\/art.38098","DOI":"10.1002\/art.38098"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.          Hansell DM, Bankier AA, MacMahon H, McLoud TC, M\u00fcller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697-722. https:\/\/doi.org\/10.1148\/radiol.2462070712","DOI":"10.1148\/radiol.2462070712"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.          Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968. https:\/\/doi.org\/10.1183\/09031936.05.00035205","DOI":"10.1183\/09031936.05.00035205"},{"key":"ref18","unstructured":"19.          Souza RB, Pereira CA. Diretrizes para testes de fun\u00e7\u00e3o pulmonar. J Pneumol. 2002;28(3):155-165."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.          Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging. 2007;22(2):120-124. https:\/\/doi.org\/10.1097\/01.rti.0000213572.16904.40","DOI":"10.1097\/01.rti.0000213572.16904.40"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.          Peelen DM, Zwezerijnen BGJC, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, et al. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology (Oxford). 2020;59(6):1407-1415. https:\/\/doi.org\/10.1093\/rheumatology\/kez483","DOI":"10.1136\/annrheumdis-2017-eular.3677"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.          Ledoult E, Morelle M, Soussan M, M\u00e9kinian A, B\u00e9hal H, Sobanski V, et al. 18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res Ther. 2021;23(1):76. https:\/\/doi.org\/10.1186\/s13075-021-02460-8","DOI":"10.1186\/s13075-021-02460-8"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.          Bellando-Randone S, Tartarelli L, Cavigli E, Tofani L, Bruni C, Lepri G, et al. 18F-fluorodeoxyglucose positron-emission tomography\/CT and lung involvement in systemic sclerosis. Ann Rheum Dis. 2019;78(4):577-578. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213376","DOI":"10.1136\/annrheumdis-2018-213376"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.          Chen DL, Rosenbluth DB, Mintun MA, Schuster DP. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol (1985). 2006;100(5):1602-1609. https:\/\/doi.org\/10.1152\/japplphysiol.01429.2005","DOI":"10.1152\/japplphysiol.01429.2005"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.          Chen DL, Cheriyan J, Chilvers ER, Choudhury G, Coello C, Connell M, et al. Quantification of Lung PET Images: Challenges and Opportunities. J Nucl Med. 2017;58(2):201-207. https:\/\/doi.org\/10.2967\/jnumed.116.184796","DOI":"10.2967\/jnumed.116.184796"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.          Lambrou T, Groves AM, Erlandsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: preliminary findings. Eur J Nucl Med Mol Imaging. 2011;38(12):2238-2246. https:\/\/doi.org\/10.1007\/s00259-011-1906-x","DOI":"10.1007\/s00259-011-1906-x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.          Schroeder T, Melo MF, Venegas JG. Analysis of 2-[Fluorine-18]-Fluoro-2-deoxy-D-glucose uptake kinetics in PET studies of pulmonary inflammation. Acad Radiol. 2011;18(4):418-423. https:\/\/doi.org\/10.1016\/j.acra.2010.11.019","DOI":"10.1016\/j.acra.2010.11.019"},{"key":"ref27","unstructured":"28.          Chen DL, Mintun MA, Schuster DP. Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury. J Nucl Med. 2004;45(9):1583-1590."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.          Win T, Screaton NJ, Porter JC, Ganeshan B, Maher TM, Fraioli F, et al. Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF). Eur J Nucl Med Mol Imaging. 2018;45(5):806-815. https:\/\/doi.org\/10.1007\/s00259-017-3917-8","DOI":"10.1007\/s00259-017-3917-8"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.          Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol. 2011;30(2):231-237. https:\/\/doi.org\/10.1007\/s10067-010-1610-4","DOI":"10.1007\/s10067-010-1610-4"},{"key":"ref30","unstructured":"31.          Bandinelli F, Del Rosso A, Gabrielli A, et al. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S44-S49."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.          Lindahl GE, Stock CJ, Shi-Wen X, Leoni P, Sestini P, Howat SL, et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res. 2013;14(1):80. https:\/\/doi.org\/10.1186\/1465-9921-14-80","DOI":"10.1186\/1465-9921-14-80"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.          Bondue B, Sherer F, Van Simaeys G, Doumont G, Egrise D, Yakoub Y, et al. PET\/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med. 2015;56(1):127-132. https:\/\/doi.org\/10.2967\/jnumed.114.147421","DOI":"10.2967\/jnumed.114.147421"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T18:58:31Z","timestamp":1663873111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jornaldepneumologia.com.br\/details\/3689\/en-US\/pet-ct-and-inflammatory-mediators-in-systemic-sclerosis-associated-interstitial-lung-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":33,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20210329","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]}}}